Vancomycin-Resistant Enterococcus faecalis Endocarditis: Linezolid Failure and Strain Characterization of Virulence Factors
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Infective endocarditis due to vancomycin-resistant (VR) Enterococcus faecalis has only rarely been reported. We report a case of VR E. faecalis endocarditis that failed to respond to linezolid therapy, outline the virulence traits of the isolate, and review previously published cases of VR E. faecalis endocarditis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, linezolid treatment failures of E faecium IE also were reported.206”
In the citing paper
“The HACEK group is usually susceptible in vitro to fluoroquinolones.206”
Citations
Cites
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 1×
“criteria for definite or possible infective endocarditis (13).”
BackgroundNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387 · cited 2×
“faecalis isolates in the United States (5, 8).”
BackgroundRole of Mobile DNA in the Evolution of Vancomycin-Resistant Enterococcus faecalis
Paulsen, I. T., Banerjei, L., Myers, G. S. A., Nelson, K. E., Seshadri, R., Read, T. D., Fouts, D. E., Eisen, J. A., Gill, S. R., Heidelberg, J. F., et al. (2003) · Science · doi:10.1126/science.1080613 · Cited by 930 · cited 1×
“a The DNA probe for the esp gene was amplified from strain MMH594, and those for all other genes were amplified from V583 (19).”
BackgroundMultiple-Drug Resistant Enterococci: The Nature of the Problem and an Agenda for the Future
Huycke, M. M., Sahm, D. F., & Gilmore, M. S. (1998) · Emerging Infectious Diseases · doi:10.3201/eid0402.980211 · Cited by 718 · cited 2×
“faecalis isolates in the United States (5, 8).”
BackgroundThe Enterococcal Surface Protein, Esp, Is Involved in Enterococcus faecalis Biofilm Formation
Toledo-Arana, A., Valle, J., Solano, C., Arrizubieta, M. J., Cucarella, C., Lamata, M., Amorena, B., Leiva, J., Penadés, J. R., & Lasa, I. (2001) · Applied and Environmental Microbiology · doi:10.1128/aem.67.10.4538-4545.2001 · Cited by 605
Shankar, V., Baghdayan, A. S., Huycke, M. M., Lindahl, G., & Gilmore, M. S. (1999) · Infection and Immunity · doi:10.1128/iai.67.1.193-200.1999 · Cited by 435
Endocarditis and biofilm-associated pili of Enterococcus faecalis
Nallapareddy, S. R., Singh, K. V., Sillanpaa, J., Garsin, D. A., Hook, M., Erlandsen, S. L., & Murray, B. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29021 · Cited by 412 · cited 1×
“These included the gelatinase gene (22, 26, 28, 30); recently described pilus-encoding genes (16); genes encoding putative MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) with predicted immunoglobulin (Ig)-like folds (17, 18, 27; J.”
BackgroundSelf-citationModulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis
Shankar, N., Baghdayan, A. S., & Gilmore, M. S. (2002) · Nature · doi:10.1038/nature00802 · Cited by 393 · cited 1×
“pothetical protein, and others (15, 24); hyaluronidases (15);”
BackgroundQin, X., Singh, K. V., Weinstock, G. M., & Murray, B. E. (2000) · Infection and Immunity · doi:10.1128/iai.68.5.2579-2586.2000 · Cited by 364 · cited 2×
“The strain was examined for phenotypic production of gelatinase (22), hemolytic activity on Bacto Tryptic Soy Agar (Becton Dickinson and Company, Sparks, MD) plus 5% human blood agar plates, and biofilm formation (14).”
BackgroundMethodSelf-citationMohamed, J. A., Huang, W., Nallapareddy, S. R., Teng, F., & Murray, B. E. (2004) · Infection and Immunity · doi:10.1128/iai.72.6.3658-3663.2004 · Cited by 297 · cited 1×
“The strain was examined for phenotypic production of gelatinase (22), hemolytic activity on Bacto Tryptic Soy Agar (Becton Dickinson and Company, Sparks, MD) plus 5% human blood agar plates, and biofilm formation (14).”
MethodSelf-citation
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“However, linezolid treatment failures of E faecium IE also were reported.(206)”
BackgroundSelf-citationGould, F. K., Denning, D. W., Elliott, T. S. J., Foweraker, J., Perry, J. D., Prendergast, B. D., Sandoe, J. A. T., Spry, M. J., & Watkin, R. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr450 · Cited by 593
Crank, C., & O'Driscoll, T. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s54125 · Cited by 505
“It has successfully treated several VRE IE cases, but treatment failures have also been reported.(39,80) Linezolid has good urine penetration at roughly 40%, but this decreases dramatically in renal dysfunction.”
Management of multidrug-resistant enterococcal infections
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03214.x · Cited by 388
“1) [49–51].”
Self-citationEmergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Self-citationNordmann, P., Naas, T., Fortineau, N., & Poirel, L. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2007.07.004 · Cited by 206
Enterococcal Disease, Epidemiology, and Implications for Treatment
Higuita, N. I. A., & Huycke, M. M. (2014) · Europe PMC (PubMed Central) · Cited by 214
Revest, M., Camou, F., Senneville, E., Caillon, J., Laurent, F. J., Calvet, B., Feugier, P., Batt, M., & Chidiac, C. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.04.014 · Cited by 124
“Linezolid has sometimes been used [125,126], most often in combination with other compounds, but its prolonged use is difficult because of its neurological and haematological toxicity and potential risk of relapse [127,128].”
BackgroundCombatting resistant enterococcal infections: a pharmacotherapy review
Mercuro, N. J., Davis, S. L., Zervos, M., & Herc, E. S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1479397 · Cited by 98
“resistance are documented with endocarditis and prolonged administration [97,99,108].”
BackgroundClinical update on linezolid in the treatment of Gram-positive bacterial infections
Gould, K. (2012) · Infection and Drug Resistance · doi:10.2147/idr.s25890 · Cited by 98
Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge
Hidalgo, L. H., Fernández-Rubio, B., Márquez, R. L., López-Cortés, L. E., Gil-Navarro, M. V., & de Alarcón, A. (2023) · Antibiotics · doi:10.3390/antibiotics12040704 · Cited by 82
Adhesion of bacteria to surfaces and biofilm formation on medical devices
Floyd, K. A., Eberly, A. R., & Hadjifrangiskou, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100382-4.00003-4 · Cited by 89
What’s New in the Treatment of Enterococcal Endocarditis?
Nigo, M., Munita, J. M., Arias, C. A., & Murray, B. E. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0431-z · Cited by 59
Self-citationEnterococcal Endocarditis: Can We Win the War?
Munita, J. M., Arias, C. A., & Murray, B. E. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0270-8 · Cited by 54
“faecium) have recently been published [44, 87–89].”
Self-citationChoi, D. G., Baek, J. H., Han, D. M., Khan, S. A., & Jeon, C. O. (2024) · BMC Genomics · doi:10.1186/s12864-023-09945-7 · Cited by 41
“In contrast, the reduced presence of virulence factor genes, ebpA (associated with pilus formation) and hylB (potentially linked to bacterial adhesion and invasion) [38], in E. faecium subclade II strains compared to E. faecium subclade I and E. lactis strains (Fig.”
ResultLinezolid for the treatment of drug-resistant infections
Herrmann, D. J., Peppard, W., Ledeboer, N. A., Theesfeld, M., Weigelt, J. A., & Buechel, B. J. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.6.825 · Cited by 43
Porcine and Human Community Reservoirs of Enterococcus faecalis , Denmark
Larsen, J., Schønheyder, H. C., Singh, K. V., Lester, C. H., Olsen, S. S., Porsbo, L. J., Migura‐García, L., Jensen, L., Bisgaard, M., Murray, B. E., et al. (2011) · Emerging infectious diseases · doi:10.3201/eid1712.101584 · Cited by 42
Self-citationTurgeon, Z. J., Jørgensen, R., Visschedyk, D. D., Edwards, P. R., Legree, S., McGregor, C., Fieldhouse, R. J., Mangroo, D., Schapira, M., & Merrill, A. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01164-10 · Cited by 36
“Bacteria use virulence factors as tools to facilitate disease in plants, animals, and humans (14, 26, 30, 34); one strategy to combat infection is to inhibit these factors by small-molecule therapy, thereby helping to neutralize the offending microbe (5, 6, 12, 19, 22).”
BackgroundYeast as a tool for characterizing mono-ADP-ribosyltransferase toxins
Turgeon, Z. J., White, D., Jørgensen, R., Visschedyk, D. D., Fieldhouse, R. J., Mangroo, D., & Merrill, A. R. (2009) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2009.01777.x · Cited by 31
“Bacteria use virulence factors as tools to facilitate disease in man (Yahr & Wolfgang, 2006; Higgins et al., 2007; Tsigrelis et al., 2007; Raghavan et al., 2008); one strategy to combat infection is to neutralize these factors by small molecule therapy, thereby helping to disarm the offending microorganism (Benghezal…”
MethodFarina, C., Russello, G., Chinello, P., Pasticci, M. B., Raglio, A., Ravasio, V., Rizzi, M., Scarparo, C., Vailati, F., Suter, F., et al. (2011) · Chemotherapy · doi:10.1159/000330458 · Cited by 30
Cobo, A., Abriouel, H., Benomar, N., López, R. L., & Gálvez, A. (2008) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2008.05.015 · Cited by 26
Chowdhury, S. A., Arias, C. A., Nallapareddy, S. R., Reyes, J., Willems, R. J. L., & Murray, B. E. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00667-09 · Cited by 19
Self-citationNasopoulou, C., Karantonis, H. C., Andriotis, M., Demopoulos, C. A., & Zabetakis, I. (2008) · Food Chemistry · doi:10.1016/j.foodchem.2008.04.011 · Cited by 18
Linezolid and Other Oxazolidinones
Cox, H. L., & Donowitz, G. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00032-1 · Cited by 17
Suleyman, G., & Zervos, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1127349 · Cited by 18
“[1,3,13,26,64] Cases of success [46] and failure [81] have been”
BackgroundCurrent Evidence on Oral Antibiotics for Infective Endocarditis: A Narrative Review
Kobayashi, T., Ando, T., Streit, J. A., & Sekar, P. (2019) · Cardiology and Therapy · doi:10.1007/s40119-019-00148-4 · Cited by 12
Haliga, R. E., Șorodoc, V., Morarasu, B. C., Coman, A. E., Ceasovschih, A., Sîrbu, O., Lionte, C., Bologa, C., Stoica, A. M., Constantin, M., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020300 · Cited by 10
“Linezolid can be used in multidrug-resistant EFIE, especially in VRE faecalis strains, but conflicting data have been reported [37,38].”
BackgroundChen, Y., Fang, S., Liu, H., Zheng, H., He, Y., Chen, Z., Chen, M., Zhang, G., & Zhou, H. (2018) · International Biodeterioration & Biodegradation · doi:10.1016/j.ibiod.2018.09.005 · Cited by 10
A comparative structure-function analysis of active-site inhibitors ofVibrio choleraecholix toxin
Lugo, M. R., & Merrill, A. R. (2015) · Journal of Molecular Recognition · doi:10.1002/jmr.2469 · Cited by 10
“…used by pathogenic bacteria to facilitate disease in plants, animals, and man (Yahr and Wolfgang, 2006; Higgins et al., 2007; Murray et al., 2007; Tsigrelis et al., 2007; Raghavan et al., 2008); one strategy to combat infection is to inhibit these factors by small molecule therapy, thereby…”
BackgroundLugo, M. R., & Merrill, A. R. (2015) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2014.1000972 · Cited by 8
Soussan, D., Salze, M., Ledormand, P., Sauvageot, N., Boukerb, A. M., Lesouhaitier, O., Fichant, G. A., Rincé, A., Quentin, Y., & Muller, C. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1070116 · Cited by 8
“This agrees with previous studies on Gram-positive pathogens, where HylA and its homologs were shown to be virulence factors (Hynes and Walton, 2000; Makris et al., 2004; Tsigrelis et al., 2006).”
Jasovich, A., Ganaha, M. C., Ebi, C., García, R., Blanco, M. Á. R., & Lopardo, H. Á. (2008) · PubMed · Cited by 10
Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent
Tan, T. Q., & Yogev, R. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.4.479 · Cited by 8
Kankaya, D. A., & Tuncer, Y. (2022) · Journal of Food Processing and Preservation · doi:10.1111/jfpp.16423 · Cited by 6
Emergence and management of drug-resistant enterococcal infections
Miller, W. R., Murray, B. E., & Arias, C. A. (2013) · Microbial Drug Resistance · doi:10.2217/ebo.12.357 · Cited by 5
Self-citationPorcine and Human Community Reservoirs of Enterococcus faecalis , Denmark
Romero, B., Rodriguez, S. M., Bezos, J., Diaz, R. V., Copano, M. F., Merediz, I., Mínguez, O., Marques, S., Palacios, J. J., de Viedma, D. G., et al. (2011) · Cited by 3
Ji, W., Zhao, Z., Lin, X., Huang, W., Chen, Q., Chen, Y., Shi, L., Xu, C., & Chen, X. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39211 · Cited by 2
“They can be considered as alternatives where cephalosporins are not susceptible to the infecting organisms [101].”
A Clinician’s Guide to the Treatment of Vancomycin Resistant Enterococci Bacteremia and Endocarditis
Soule, D., & Climo, M. W. (2016) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-016-0082-8 · Cited by 2
Enterococci: Resistance Update and Treatment Options
Linden, P. K. (2007) · CRC Press eBooks · doi:10.1201/b15169-6 · Cited by 3
Endocardite à Enterococcus faecalis traitée avec succès par la daptomycine
Bonnet, É. (2008) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(08)75151-5 · Cited by 1
Linezolid and Other Oxazolidinones
Donowitz, G. R., & Cox, H. L. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00033-3 · Cited by 1
Clinical Aspects of Multi-Drug Resistant Enterococci
Contreras, G., & Arias, C. A. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1400-1_19
Makinson, A., & Moing, V. L. (2008) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2008.02.008
High-Level Aminoglycoside-Resistant Enterococcal Endocarditis: A Therapeutic Challenge
Muir, A., Pillay, D. G., & Hill, R. L. R. (2012) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e31825aee03
Advances in the Diagnosis and Treatment of Infective Endocarditis
Turner, R. B., & Schwartz, J. (2017) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-2092-4.ch010
Choi, D. G., Baek, J. H., Han, D. M., Khan, S. A., & Jeon, C. O. (2024) · Figshare · doi:10.6084/m9.figshare.24940448
Choi, D. G., Baek, J. H., Han, D. M., Khan, S. A., & Jeon, C. O. (2024) · Figshare · doi:10.6084/m9.figshare.26660545
Choi, D. G., Baek, J. H., Han, D. M., Khan, S. A., & Jeon, C. O. (2024) · Figshare · doi:10.6084/m9.figshare.24941004
Salze, M. (2019) · theses.fr (ABES) · doi:10.70675/2a583cf7z64ecz48d6z81c1zbe0e5512752f · Cited by 2
Etude de la régulatiοn du métabοlisme des bêta-glucοsides chez les entérοcοques d'interêt clinique
Soussan, D. (2024) · theses.fr (ABES) · doi:10.70675/009980e0z6d2az4625z8f6az18c2d36b3c6c
Schlüter, S. (2009) · Kobra (Universitätsbibliothek Kassel)
Metadata
- Authors
- Tsigrelis, C., Singh, K. V., Coutinho, T. D., Murray, B. E., & Baddour, L. M.
- Affiliations
- Mayo Clinic (US)
- Division of Infectious Diseases, Department of Medicine
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Tsigrelis, Constantine
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2007-02
- Volume
- 45
- Issue
- 2
- Pages
- 631-635
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC1829077
- OpenAlex
- W1984425763
- Semantic Scholar
- 641ef3c32c510a702f5bb29c5d2b0a0f1f9f0a0c
- Cited by
- 48
- References
- 36
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 7 · 2014: 2 · 2013: 1 · 2012: 3
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R37AI47923, R37AI047923)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- vancomycin-resistant Enterococcus faecalis, infective endocarditis, virulence factors, antimicrobial resistance, strain characterization
- MeSH terms
- Linezolid, Acetamides, Adult, Anti-Infective Agents, Bacterial Proteins, Endocarditis, Bacterial, Female, Humans, Enterococcus faecalis, Virulence, Gram-Positive Bacterial Infections, Treatment Failure, Vancomycin Resistance, Oxazolidinones, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.